First- and Second-Line Treatment Options in Lower-Risk MDS

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Related Videos
Jorge E. Cortes, MD
Julie Renee Brahmer, MD
Bradley W. Christensen, MD
Anne Chiang, MD, PhD, associate professor, medical oncology, Yale School of Medicine, associate cancer center director, Clinical Initiatives, Smilow Cancer Hospital, Yale Cancer Center
Expert on CSCC
Expert on CSCC
Experts on BTC
Experts on BTC
Aaron Gerds, MD, an expert on myeloproliferative neoplasms
Expert on AML
Related Content